Promising fragile x drug moves to Long-Term safety check
Disease control
Ongoing
This study looks at the long-term safety of a drug called BPN14770 in people with Fragile X syndrome. It includes about 314 adults and teens who already completed earlier studies of the drug. Everyone in this study will receive the drug for up to 4 years, and researchers will mon…
Phase: PHASE3 • Sponsor: Tetra Discovery Partners • Aim: Disease control
Last updated May 12, 2026 13:43 UTC